Effective 1 July 2024, the PHN discontinued the use of Capacity Tracker®. Introduced during the COVID-19 pandemic, Capacity Tracker® was essential in managing infection control supplies and COVID-19 vaccination resources.
This research aims to investigate the facilitators and barriers to pharmacist administered vaccination services from the perspective of the Australian pharmacist.
Empowering small rural communities with innovative healthcare solutions.
Aimed at enhancing the accuracy of healthcare service and practitioner information, Hunter New England Central Coast Primary Health Network (the PHN) collaborated with the Australian Digital Health Agency (ADHA) to host an education session on Provider Connect Australia™ (PCA™).
Attention General Practice Nurses and Community Pharmacists! Your voice matters! Researchers at the Monash University, SPHERE Centre of Research Excellence, invite you to participate in a ground-breaking national survey about providing women’s sexual and reproductive health services.
A Better Health for the Bush Initiative
The Hunter New England and Central Coast Primary Health Network (the PHN) has successfully secured pilot funding under the Federal Government’s Innovative Models of Care (IMOC) Program, which will see Glen Innes as a pilot site to introduce an innovative healthcare model.
We are delighted to share an initiative by the Australian Digital Health Agency that aims to enhance the digital health literacy of health care professionals, both patients and their carers. In an era where technology is transforming the healthcare landscape, healthcare professionals must guide their patients in navigating and utilising digital health tools effectively.
The PHN is informing primary care providers that on 24/11/2023, the Public Health and Surveillance Branch in the Office of Health Protection of the Department of Health and Aged Care has issued a quarantine notice for the product; InterPharma Sodium Chloride 0.9% 10ml or 30ml ampoules.
Changes to ATAGI guidelines: Monovalent COVID-19 vaccines - As our regions faces increasing numbers of COVID-19 cases, the Australian Technical Advisory Group on Immunisation (ATAGI) has issued updated advice regarding the use of Monovalent Omicron XBB.1.5 COVID-19 vaccines.
From 1 November 2023, the varicella virus recombinant vaccine, Shingrix ®, replaces Zostavax®, on the National Immunisation Program (NIP) schedule for the prevention of shingles and post-herpetic neuralgia. It is available for eligible people most at risk of complications from shingles (1). The program changes follow recommendations from the Pharmaceutical Benefits Advisory Committee, the Australian Technical Advisory Group on Immunisation (ATAGI) and other clinical experts (1).